{"database": "press", "table": "releases", "rows": [["https://www.manchin.senate.gov/public/index.cfm/press-releases?ContentRecord_id=93BAFC45-C380-401B-B2FA-951A692FA3F8", "Manchin Applauds DEA Decision to Lower Opioid Quotas", "2016-10-06", "2016", "2016-10", "Democrat", "House", "WV", "Joe Manchin", "M001183", "www.manchin.senate.gov", null, null, "legacy", "Washington, D.C. \u2013 U.S. Senator Joe Manchin (D-WV) along with Senators Amy Klobuchar, Dick Durbin (I-IL), Sherrod Brown (D-OH), Edward Markey (D-MA) and Angus King (I-ME) today commended the Drug Enforcement Administration\u2019s (DEA) decision to lower opioid quotas. Earlier this year, Manchin and the other Senators sent a letter urging DEA Acting Administrator Rosenberg to use the agency\u2019s quota-setting authority to limit the quantity of opioid pills on the market. The DEA announced this week that it has decided to reduce next year\u2019s production quotas by 25 percent for nearly all Schedule II drugs, including prescription opioids. The three powerful, addictive painkillers that will see the most significant reductions from what was allowed on the market this year are hydrocodone (34% reduction), oxymorphone (45% reduction), and hydromorphone (38% reduction).\r\n\u201cThis decision from the DEA brings us one step closer to curbing this opioid epidemic and I applaud their commitment to reversing this trend,\u201d Senator Manchin said. \u201cThere are simply too many opioid pills on the market and \u200ethe DEA is an important partner in addressing that problem. This decision will cut next year\u2019s production quota\u2019s by 25 percent which will greatly reduce the amount of opioids available for prescription. We must keep working with everyone to combat this epidemic from all sides and the DEA decision is another turning point in our fight.\u201d\r\nWith its existing quota-setting authority, the DEA effectively serves as a gatekeeper for how many opioids can be produced and sold in the United States every year. Over\u200e the past two decades, the DEA had approved ever-greater increases in opioid quotas, allowing production of oxycodone to increase 39-fold, hydrocodone to increase 12-fold, hydromorphone to increase 23-fold, and fentanyl to increase 25-fold. This week\u2019s announcement represents the largest decrease in opioid production quotas in two decades.\r\nThe Senators also welcomed the DEA\u2019s announcement that it had considered the impact of the Centers for Disease Control and Prevention\u2019s (CDC) \u201cGuideline for Prescribing Opioids for Chronic Pain\u201d on doctors\u2019 prescribing practices in determining the quantities of prescription opioids required to meet legitimate medical and scientific need.\r\nFor a full list of Senator Manchin\u2019s legislation to combat the opioid abuse epidemic, click here. \r\n\u00a0\r\n###", 1, "2026-03-30T12:14:52Z", "2026-03-30T12:14:52Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://www.manchin.senate.gov/public/index.cfm/press-releases?ContentRecord_id=93BAFC45-C380-401B-B2FA-951A692FA3F8"], "units": {}, "query_ms": 0.8193012326955795, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}